Abstract
Background: Kits (combinations of immune-modulatory compounds: GM-CSF+Picibanil (Kit-I), Prostaglandine (PG-E2,Kit-K) or +PGE1 (Kit-M), patent 102014014993) convert myeloid blasts into dendritic cells of leukemic origin (DCleu). After stimulation with DCleu, antileukemic T-cells can be generated ex vivo. Compounds are approved for clinical use and are attractive tools for immunotherapy in myeloid leukemia.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.